about
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.The CD47 pathway is deregulated in human immune thrombocytopenia.Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseImpact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyManagement of acute graft versus host disease (GvHD).The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.Response definitions and European Leukemianet Management recommendations.Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.Treatment recommendations for chronic myeloid leukemiaDefinition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyNew strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and SplenomegalyAssessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainDeletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.
P50
Q33376325-D768D905-F5E2-4872-9963-15C67330DE73Q33393546-A644D3E2-969D-4E78-B3A0-5ACBA3492C78Q33403052-7A6D7CE1-7BC0-491A-9DDE-8AF64F396915Q33404320-3DA98971-52FE-4403-9034-2F1B32A519F5Q33415996-0C4D4590-B488-413E-A6AE-68A4F67242B1Q33416947-822FE026-C227-48A8-8015-6C7BAB424975Q33429426-15191162-958D-4B0B-B893-8939F018B802Q33437373-6B69C992-16CC-473E-A8E7-EB13FF8F33C0Q33437682-62E1C605-4BB4-413B-91BC-726DB73E9427Q33441917-C2D14D5C-E62F-4421-926E-B74019DF4831Q34032263-5C6CED7B-9B9F-4E48-AF0F-86FA6680231AQ35636700-42EF78DB-AE14-4CC7-87E5-310127DF3ECCQ35787236-8BF92171-4012-4870-A247-4DDBB311F532Q37082725-35D6C32F-3B6C-4810-98F9-F04BDE478491Q37470939-B524FD55-4430-4A00-B960-E55FEDEE3F61Q37644004-313ECE03-1C95-4916-BDC6-52703E2191C8Q37714887-36C9DC17-94A9-47DF-AE30-776892AD33D9Q37874788-1AEEF4FB-EB57-4036-B763-ED364E3B4627Q37917120-F24D925F-53F3-4FC2-81B3-460153FAF3B2Q38181112-C47E7C96-3F29-4519-9BB9-5A0568AD5690Q38199143-4FE2BBA3-F96E-41CF-9972-EE034915F60FQ38386719-1CD8052E-C8FF-467E-BA78-E46F1731D06CQ38814941-3B403309-FF1F-420B-A017-F433A19B9120Q38830536-0638290A-3F98-4720-85E9-A5ADBA344EE4Q38924189-5806E90C-C5C1-4EA2-A976-B9342CDC4460Q39986585-980C9A11-1B50-4CF9-8C58-39E953EF47AFQ40125614-3D2D9D67-B400-4CE4-8743-35F36D86943AQ40564541-948CD4FE-E752-4521-8E8C-D28EE03072C3Q42062133-CE17FB2C-E5EF-488B-AB86-30AD829B8964Q42811718-E4BF70F1-389C-4542-B819-B224BD06E49BQ43075393-E813EC73-2B1C-4F1B-BF97-809D05054632Q43262982-840D729F-1B6E-4DD3-A16E-65684A093778Q44217288-AF80944E-B620-4B4B-903C-B284D00DCFF4Q44753123-6F274237-3B9C-4C95-BE51-F2863B5A11E0Q44912433-EF7235EA-AF06-48A5-B708-DB986F8D6F81Q45236578-48713C58-0C7A-4FA8-B877-A958A85B1E68Q45912397-4A84A94F-1C3A-4679-A991-CEB22564586EQ45933610-E591B61F-AF2B-4EC8-B95B-82CAD8B46DFBQ45969980-803DD7EC-80F7-4B4E-981F-020D95F8A085Q46113435-49BD2287-7535-47FE-A66A-ED98E6BB135E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesca Palandri
@ast
Francesca Palandri
@en
Francesca Palandri
@es
Francesca Palandri
@nl
type
label
Francesca Palandri
@ast
Francesca Palandri
@en
Francesca Palandri
@es
Francesca Palandri
@nl
prefLabel
Francesca Palandri
@ast
Francesca Palandri
@en
Francesca Palandri
@es
Francesca Palandri
@nl
P106
P1153
23009859900
P21
P31
P496
0000-0001-8367-5668